A Phase 1, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics of TQA3038 Injection in Healthy Adult Subjects.
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
This is a phase 1 study in which healthy adult subjects will receive TQA3038 or placebo and will be assessed for safety, tolerability, pharmacokinetics. In the single ascending dose (SAD) part, healthy adult subjects will receive one dose of TQA3038 or placebo, administered subcutaneously (SC).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 60
Healthy Volunteers: t
View:
• Male or female age 18～60 years.
• Body mass index (BMI) 19 - 26 kg/m\^2.
Locations
Other Locations
China
Tongji Hospital
RECRUITING
Wuhan
Contact Information
Primary
Dong Liu, Doctor
ld_2069@163.com
+86 13507183749
Backup
ZheLong Liu, Doctor
liuzhelong@163.com
+86 13986235028
Time Frame
Start Date: 2023-11-30
Estimated Completion Date: 2025-12
Participants
Target number of participants: 54
Treatments
Experimental: TQA3038 injection
One dose of TQA3038 injection in Day 1.
Placebo_comparator: TQA3038 injection matching placebo
One dose of TQA3038 injection matching placebo in Day 1.
Related Therapeutic Areas
Sponsors
Leads: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.